Therefore, we believe that targeting ML-323 or USP1 can increase the sensitivity of HCC cells to sorafenib treatment by inhibiting the expression of cyclin E1, cyclin D1, CDK2, and CDK4. Here, CCNE1 is linked to hepatocellular carcinoma.